Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alectinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 20/20 | 0.98 |
| ▸ | EML4 known ✓ | Q9HC35 | 2/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.98 |
| ▸ | KDR | P35968 | 5/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ROS1 | P08922 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.98 |
| ▸ | FER | P16591 | 1/20 | 0.98 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alectinib SCHEMBL29360318 | 1.00 | ALK (0.98) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL896753 | 0.99 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL18631602 | 0.99 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL29352499 | 0.99 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| Alectinib SCHEMBL31372326 | 0.98 | ALK (0.98) | ALKKDREML4GAKACOX3 | |
| SCHEMBL896761 | 0.94 | ALK (1.00) | ALKKDREML4GAKACOX3 | |
| SCHEMBL898391 | 0.93 | ALK (0.89) | ALKKDREML4GAKACOX3 | |
| SCHEMBL29962525 | 0.93 | ALK (0.89) | ALKKDREML4GAKACOX3 | |
| SCHEMBL898293 | 0.92 | ALK (0.87) | ALKKDREML4GAKACOX3 | |
| SCHEMBL29962638 | 0.92 | ALK (0.87) | ALKKDREML4GAKACOX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134900-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2025-05-01 | — | — | US | claimed |
| US-20240299403-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2024-09-12 | — | — | US | claimed |
| US-12005064-B2 | Pharmaceutical composition comprising non-ionic surfactants | HOFFMANN-LA ROCHE INC. (US) | 2024-06-11 | — | — | US | claimed |
| CN-110960500-B | Novel pharmaceutical compositions comprising nonionic surfactants | 豪夫迈·罗氏有限公司 | 2022-10-14 | — | — | CN | claimed |
| US-11433076-B2 | Preparation containing tetracyclic compound at high dose | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-06 | — | — | US | claimed |
| US-20200397794-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-24 | — | — | US | claimed |
| CN-110960500-A | Novel pharmaceutical compositions comprising nonionic surfactants | 豪夫迈·罗氏有限公司 | 2020-04-07 | — | — | CN | claimed |
| EP-3157569-B1 | NEW PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN LA ROCHE (CH) | 2019-07-24 | — | — | EP | claimed |
| US-20170119781-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2017-05-04 | — | — | US | claimed |
| EP-3157569-A1 | NEW PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | F. Hoffmann-La Roche AG (CH) | 2017-04-26 | — | — | EP | claimed |
| WO-2015193309-A1 | NEW PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-23 | — | — | WO | claimed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250134900-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | HOFFMANN-LA ROCHE INC. (US) | 2025-05-01 | — | — | US | disclosed |
| EP-3848361-B1 | METHOD OF PRODUCING TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-20160317494-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-03 | — | — | US | disclosed |
| US-9365514-B2 | Composition comprising tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-06-14 | — | — | US | disclosed |
| WO-2015193309-A1 | NEW PHARMACEUTICAL COMPOSITION COMPRISING NON-IONIC SURFACTANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-23 | — | — | WO | disclosed |
| EP-2606886-A1 | COMPOSITION CONTAINING TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885EML4 2904/4885RET 96/4885 |
| US-20160317494-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885EML4 2904/4885RET 96/4885 |
| US-11433076-B2 | Preparation containing tetracyclic compound at high dose | CALU, BECN1, TIA1 | ALK 3891/4885EML4 812/4885RET 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.